Things
Public call for the selection of project proposals to be financed as part of the research activities of Spoke 3 "Neurodegeneration", referred to in the research program of the National Center for Development of Gene Therapy and Drugs with RNA Technology "National Center For Gene Therapy And Drugs Based On Rna Technology (Cn Rna & Gene Therapy)", drawing on the resources of the National Recovery and Resilience Plan (PNRR), Mission 4 "Education and research", Component 2 "from research to business", Investment line 1.4 “Strengthening research structures and creating national R&D champions on some key enabling technologies”.
Who is it aimed at?
The call is aimed at: - Micro, Small and Medium Enterprises (MSMEs), external to the National Center and which compete in single mode, having the dimensional parameters referred to in Annex I of REG (EC) n. 800/2008 of the Commission of 6 August 2008 (General block exemption regulation) in OJEU L 214 of 9.8.2008, including innovative start-ups; - Large Enterprises (GI), external to the National Center and competing in single mode ;- Public research bodies and institutions, including universities, and the bodies referred to in Legislative Decree no. 218/2016 (https://www.mur.gov.it/it/aree-tematiche/ricerca/il-sistema-della-ricerca/enti-di-ricerca-pubblici); - Scientific Hospitalization and Care Institutes - IRCCS, whether public or private in nature; - Bodies referred to in the Third Sector Code - Legislative Decree 3 July 2017 n.117 and subsequent amendments.
What does it predict
The Istituto Italiano di Tecnologia Foundation, as Implementer of the CN RNA & Gene Therapy Research Program (Spoke #3, Neurodegeneration), coordinates the activities of a network of research centers and laboratories, large-scale demonstration environments, applications full-scale prototypes, to achieve the following objectives: - Identify target RNA molecules for the treatment of central nervous system diseases - Identify natural or synthetic RNA molecules that can be used as drugs - Validation of these molecules in patient-derived cells and in animal models of disease - Collection of preclinical data that allow the approval as Investigational New Drug (IND) of candidate RNA molecules. On 12.01.2024, the execution of the first window of the call began in which 1,300 were allocated €,000. With this notice we intend to start the opening of the second window.
